Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical…
MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses…
TORONTO and SAN DIEGO (June 4, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced positive results from its…
TORONTO (May 11, 2016) – Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and…
MaRS Innovation and the Ontario Centres of Excellence among the event's sponsors On Tuesday, May 31, 2016, Diane Francis, the first woman editor of a national daily newspaper in Canada…
Montreal-based venture capital fund and entrepreneurship program brings over $20 million in funding and deep expertise in consumer electronics to MI members; first deal in speech recognition TORONTO and MONTREAL,…
TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST).
UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 in funding, with opportunities for follow-on funding from MaRS Innovation.
In 2014, UTEST was named one of Canada’s most promising start-up accelerators in an online series by BetaKit, a digital publication that covers Canadian technology.
“We are thrilled to partner with A&B and leverage their legal expertise for our startups and emerging companies,” said Kurtis Scissions, who co-directs UTEST with MI’s Mike Betts. “To date, 17 companies, including Granata Decision Systems, Whirlscape, Crowdmark, eQOL and TrendMD, have successfully graduated from our program. We look forward to adding A&B’s Startups Team of lawyers to our mentorship group for the UTEST program, beginning in 2015.”
Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies
TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer’s disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million contribution to the Neuroscience Catalyst consortium, bringing the total raised for the open innovation fund to $3.7 million. Reza Moridi, Minister of Research and Innovation and Minister of Training Colleges and Universities, announced the contribution at the 2015 BIO International conference in Philadelphia during the opening of the Ontario pavilion.
This release was covered by Pharma TV and in TechVibes, BioSpace and Biotechnology Focus, and was referenced on the Canadian Science Policy Centre‘s and the Alzheimer Society of Toronto’s respective websites.
“We are pleased to support this collaborative innovation model which will accelerate the development of better treatment options for people with neurological disorders,” said Minister Moridi. “Partnerships between universities, academic hospitals, research institutes, industries and government are key to positioning Ontario as a global leader in Life Sciences.”
Founded by the University of Toronto (U of T) in partnership with Janssen Inc. and facilitated by Johnson & Johnson Innovation, the Neuroscience Catalyst consortium is using the Toronto research community’s well-established strengths in neuroscience to identify promising early-stage molecules and technologies through an open innovation model. The consortium aims to combine expertise to enable and accelerate the translation of basic sciences through to start-up companies and investor partnerships.
“We all want the next generation of solutions that are so desperately needed by patients and their families,” said Professor Ruth Ross, director of the Centre for Collaborative Drug Research at U of T. “In Canada, mood disorders such as depressive disorder and bipolar disorder affect about 10 per cent of the population. Alzheimer’s disease affects more than 745,000 Canadians. The need is urgent and this unique open collaborative partnership will allow us to rapidly develop new treatments.”
Other partners joining the project include MaRS Innovation, which introduced the partners to the Ministry of Research & Innovation and led the early conversation; Evotec, a global, high-quality provider in the drug discovery field; and Ontario Centres of Excellence (OCE), which is administering the funding.
TORONTO, Jan. 12, 2015 — MaRS Innovation, the commercialization agent for Ontario’s 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively.
This announcement was covered in Lab Product News.
“These three projects reflect the quality of innovation present in Toronto’s research community for our industry partners, and Toronto’s progress in addressing healthcare issues of international concern,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Johnson & Johnson Innovation is a long-term strategic partner of MaRS Innovation and of our members; our collaboration reflects the benefits to accessing our members’ deal flow through MaRS Innovation. Through these deals and other scientific exchanges, we see increased interest in Toronto’s innovation and entrepreneurship community.”
The projects’ principal investigators are researchers from the University Health Network (UHN), the Centre for Addiction and Mental Health (CAMH) and the University of Toronto. This announcement follows Johnson & Johnson Innovation’s December 2013 commitment to collaborate on early-stage drug development projects.
MI portfolio company actively seeking additional products for licensing and development
TORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator.
Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the time and expense between an investigational new drug application and “proof-of-concept” at Phase II.
Triphase, spun out of the Ontario Institute for Cancer Research (OICR), develops and advances late pre-clinical, Phase I or early Phase II potential products. Triphase and its founding investors are in a position to take advantage of the excellent research and development capabilities in the Toronto healthcare and innovation ecosystem.
The Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation Ventures Trust, and MaRS Phase II Investment Trust, are all Toronto-based equity investors in Triphase.
After company formation, Triphase entered into a strategic relationship with Celgene Corporation. Through this arrangement, Celgene obtained rights of first refusal on the first three oncology products Triphase advances to clinical proof-of-concept (POC), plus a right of first negotiation on three more future oncology products which may be acquired by Triphase.